. "3 Guidelines, Standards, Oversight, and Incentives Needed for Biomarker Development." Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Washington, DC: The National Academies Press, 2007.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment
Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. 2005. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal ofClinical Oncology 23(28):6829-6837.
Tan PK, Downey TJ, Spitznagel EL Jr, Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM, Cam MC. 2003. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Research 31(19):5676-5684.
Waring P. March 20, 2006. Therapeutics industry perspectives/realities (examples of successes and difficulties/failures of targeted therapy). Presentation at the IOM workshop on Developing Biomarker-based Tools for Cancer Screening, Diagnosis, and Treatment. Washington, DC.
Woodcock J. Deputy Commissioner for Operations FDA. 2006. Personal communication.